RECURRENT NODULAR LYMPHOCYTE PREDOMINANT B-CELL LYMPHOMA

Clinical trials for RECURRENT NODULAR LYMPHOCYTE PREDOMINANT B-CELL LYMPHOMA explained in plain language.

Never miss a new study

Get alerted when new RECURRENT NODULAR LYMPHOCYTE PREDOMINANT B-CELL LYMPHOMA trials appear

Sign up with your email to follow new studies for RECURRENT NODULAR LYMPHOCYTE PREDOMINANT B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Head-to-Head trial tests new drug against standard for rare lymphoma

Disease control Recruiting now

This study is testing whether a newer drug called mosunetuzumab is better than the standard drug rituximab at keeping a rare, slow-growing lymphoma from getting worse. About 70 adults with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) will be randomly assigned to receiv…

Matched conditions: RECURRENT NODULAR LYMPHOCYTE PREDOMINANT B-CELL LYMPHOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

RECURRENT NODULAR LYMPHOCYTE PREDOMINANT B-CELL LYMPHOMA

Get alerted when new RECURRENT NODULAR LYMPHOCYTE PREDOMINANT B-CELL LYMPHOMA trials appear

Head-to-Head trial tests new drug against standard for rare lymphoma